TY - JOUR T1 - Comparison of 6-<sup>18</sup>F-Fluorodopamine PET with <sup>123</sup>I-Metaiodobenzylguanidine and <sup>111</sup>In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1613 LP - 1619 DO - 10.2967/jnumed.108.052373 VL - 49 IS - 10 AU - Ioannis Ilias AU - Clara C. Chen AU - Jorge A. Carrasquillo AU - Millie Whatley AU - Alexander Ling AU - Ivica Lazúrová AU - Karen T. Adams AU - Shiromi Perera AU - Karel Pacak Y1 - 2008/10/01 UR - http://jnm.snmjournals.org/content/49/10/1613.abstract N2 - We compared functional imaging modalities including PET with 6-18F-fluorodopamine (18F-DA) with 123I-metaiodobenzylguanidine (123I-MIBG) and somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age ± SD, 44.2 ± 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: 18F-DA PET, 123I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis. Results: For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for 18F-DA PET, 76.0% for 123I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for 18F-DA PET, 63.4% for 123I-MIBG scintigraphy, and 64.0% for SRS. Conclusion: If available, 18F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than 123I-MIBG scintigraphy or SRS. If 18F-DA PET is not available, 123I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used. ER -